Switch theme
Sign up to access all valuation multiples
Replek AD is engaged in the development, design and production of generic medicines. The company develops drugs in different pharmaceutical therapeutic categories including anti-platelet, lipid-lowering, atypical antipsychotic, anti-infective, among others. It manufactures drugs in different forms including tablets, capsules, oral solutions, creams and ointments. Its product portfolio consists of Clopidogrel, Atorvastatin, Simvastatin, risperidone, Clarythromycin, Ciprofloxacin, Meloksikam, Risperidon, terazosin, among others. Replek also offers cannabis oil products, food supplements and cosmetics.
1945
408
Last FY Revenue $35.3M
Last FY EBITDA $7.1M
$82.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Replek achieved revenue of $35.3M and an EBITDA of $7.1M.
Replek expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Replek valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $35.3M | XXX | XXX | XXX |
| Gross Profit | XXX | $18.7M | XXX | XXX | XXX |
| Gross Margin | XXX | 53% | XXX | XXX | XXX |
| EBITDA | XXX | $7.1M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 20% | XXX | XXX | XXX |
| EBIT | XXX | $5.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | 14% | XXX | XXX | XXX |
| Net Profit | XXX | $4.1M | XXX | XXX | XXX |
| Net Margin | XXX | 12% | XXX | XXX | XXX |
| Net Debt | XXX | $5.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Replek's stock price is MKD 16001 (or $294).
Replek has current market cap of MKD 4.1B (or $76.3M), and EV of MKD 4.5B (or $82.0M).
See Replek trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $82.0M | $76.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Replek has market cap of $76.3M and EV of $82.0M.
Replek's trades at 2.3x EV/Revenue multiple, and 11.6x EV/EBITDA.
Equity research analysts estimate Replek's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Replek's P/E ratio is not available.
See valuation multiples for Replek and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $76.3M | XXX | $76.3M | XXX | XXX | XXX |
| EV (current) | $82.0M | XXX | $82.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 11.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 16.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 18.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 23.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialReplek's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $33K for the same period.
Replek's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Replek's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Replek and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $33K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Replek acquired XXX companies to date.
Last acquisition by Replek was XXXXXXXX, XXXXX XXXXX XXXXXX . Replek acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Replek founded? | Replek was founded in 1945. |
| Where is Replek headquartered? | Replek is headquartered in Macedonia. |
| How many employees does Replek have? | As of today, Replek has 408 employees. |
| Is Replek publicy listed? | Yes, Replek is a public company listed on MAE. |
| What is the stock symbol of Replek? | Replek trades under REPL ticker. |
| Who are competitors of Replek? | Similar companies to Replek include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Replek? | Replek's current market cap is $76.3M |
| Is Replek profitable? | Yes, Replek is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
